Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive HF
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): B Cell, Burkitt Lymphoma Cell Line
DISEASE(S): Burkitt Lymphoma
SUBMITTER: Anne Wilke
LAB HEAD: Thomas Oellerich
PROVIDER: PXD018961 | Pride | 2023-03-10
REPOSITORIES: Pride
Items per page: 5 1 - 5 of 146 |
Wilke Anne C AC Doebele Carmen C Zindel Alena A Lee Kwang Seok KS Rieke Sara A SA Ceribelli Michele M Comoglio Federico F Phelan James D JD Wang James Q JQ Pikman Yana Y Jahn Dominique D Häupl Björn B Schneider Constanze C Scheich Sebastian S Tosto Frances A FA Bohnenberger Hanibal H Stauder Philipp P Schnütgen Frank F Slabicki Mikolaj M Coulibaly Zana A ZA Wolf Sebastian S Bojarczuk Kamil K Chapuy Björn B Brandts Christian H CH Stroebel Philipp P Lewis Caroline A CA Engelke Michael M Xu Xincheng X Kim Hahn H Dang Thanh Hung TH Schmitz Roland R Hodson Daniel J DJ Stegmaier Kimberly K Urlaub Henning H Serve Hubert H Schmitt Clemens A CA Kreuz Fernando F Knittel Gero G Rabinowitz Joshua D JD Reinhardt Hans Christian HC Vander Heiden Matthew G MG Thomas Craig C Staudt Louis M LM Zenz Thorsten T Oellerich Thomas T
Blood 20220101 4
Burkitt lymphoma (BL) is an aggressive lymphoma type that is currently treated by intensive chemoimmunotherapy. Despite the favorable clinical outcome for most patients with BL, chemotherapy-related toxicity and disease relapse remain major clinical challenges, emphasizing the need for innovative therapies. Using genome-scale CRISPR-Cas9 screens, we identified B-cell receptor (BCR) signaling, specific transcriptional regulators, and one-carbon metabolism as vulnerabilities in BL. We focused on s ...[more]